• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    11/6/24 5:04:05 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBIO alert in real time by email
    SC 13D/A 1 bbio.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13D
    (Amendment No. 4)*

    BridgeBio Pharma, Inc.
    (Name of Issuer)

    Common Stock, par value $0.001 per share
    (Title of Class of Securities)

    10806X102
    (CUSIP Number)

    Matthew Bloom
    General Counsel and Chief Compliance Officer
    600 Washington Boulevard, Floor 11
    Stamford, Connecticut 06901
    (212) 672-7059
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    August 16, 2024**
    (Date of Event Which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box: ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    ** This Amendment No. 4 is being filed solely to change the person authorized to receive notices and communications.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 2 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Investors LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4%  (see Item 5) (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

     
    1.
    All share percentage calculations in this Amendment No. 4 to the Schedule 13D are based on 188,032,738 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the “Issuer”) outstanding as of July 25, 2024, as reported in the Issuer’s quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the “Commission”) on August 1, 2024.


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 3 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Performance LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    631,167 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.3% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 4 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Equities Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    631,167 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    631,167 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.3% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 5 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    251,204 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.1% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 6 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Long Fund Master Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    251,204 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    251,204 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.1% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 7 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Parent GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9%  (see Item 5) (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 8 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 9 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Portfolio GP LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 10 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,238,620 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,238,620 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    12.9% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 11 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    O. Andreas Halvorsen
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Norway
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 12 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    David C. Ott
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 13 of 15
    1
    NAMES OF REPORTING PERSONS
     
     
    Rose S. Shabet
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO - other
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0 (see Item 5)
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0 (see Item 5)
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    25,120,991 (see Item 5)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    25,120,991 (see Item 5)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    13.4% (see Item 5)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 14 of 15
    EXPLANATORY NOTE

    Pursuant to Rule 13d-2 of the Securities Exchange Act of 1934, as amended, this Amendment No. 4 to the Schedule 13D (“Amendment No. 4”) amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023 and Amendment No. 3 filed with the Commission on August 20, 2024 (collectively, the “Schedule 13D”) relating to the Common Stock, par value $0.001 per share (the “Common Stock”) of BridgeBio Pharma, Inc., a Delaware corporation (the “Issuer”). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

    This Amendment No. 4 is being filed solely to change the person authorized to receive notices and communications on the first page of the Schedule 13D.


    CUSIP No: 10806X102
    SCHEDULE 13D
    Page 15 of 15
    SIGNATURES
     
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Dated: November 6, 2024     

        

    By:
    /s/ Scott M. Hendler

    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)

    By:
    /s/ Scott M. Hendler

    Name:
    Scott M. Hendler on behalf of David C. Ott (2)

    By:
    /s/ Scott M. Hendler

    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Ott on February 12, 2021 (SEC File No. 005-49737).

    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, and VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Ms. Shabet on February 12, 2021 (SEC File No. 005-49737).



    Get the next $BBIO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBIO

    DatePrice TargetRatingAnalyst
    6/3/2026$104.00Buy
    Canaccord Genuity
    5/26/2026Outperform → Mkt Perform
    Raymond James
    5/19/2026$82.00Neutral
    Citigroup
    4/9/2026$100.00Outperform
    RBC Capital Mkts
    3/10/2026Outperform
    William Blair
    1/28/2026$157.00Overweight
    Barclays
    1/6/2026$96.00Overweight
    Morgan Stanley
    12/11/2025$94.00Outperform
    Bernstein
    More analyst ratings

    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on BridgeBio Pharma with a new price target

    Canaccord Genuity initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $104.00

    6/3/26 8:10:28 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma downgraded by Raymond James

    Raymond James downgraded BridgeBio Pharma from Outperform to Mkt Perform

    5/26/26 8:28:10 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on BridgeBio Pharma with a new price target

    Citigroup initiated coverage of BridgeBio Pharma with a rating of Neutral and set a new price target of $82.00

    5/19/26 8:29:29 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by BridgeBio Pharma Inc.

    SCHEDULE 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    7/10/26 7:03:31 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)

    7/2/26 4:23:41 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)

    6/26/26 8:30:33 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:49:25 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:46:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valantine Hannah bought $44,476 worth of shares (3,433 units at $12.96) (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/13/24 4:00:10 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on July 7, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 37 new employees in restricted stock units for an aggregate of 83,283 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on August 16, 2027, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, sub

    7/10/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM

    - Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no kidney-related adverse events observed in these post-hoc analyses -Treatment with acoramidis provided a sustained, improved chronic eGFR slope (+2.47 mL/min/1.73m²/year; p<0.001) sustained UACR reduction (13.7%; p=0.026) through Month 30 - Acoramidis demonstrated a profile consistent with drugs that act directly on the kidney, such as ACE inhibitors, ARBs, and SGLT2 inhibitors, which has not previously been observed with any other approved ATTR-CM therapy and supports a direct

    7/2/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

    - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr

    7/1/26 7:30:00 AM ET
    $BBIO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ellis Andrea exercised 17,167 shares at a strike of $16.75 and sold $1,442,028 worth of shares (17,167 units at $84.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    7/13/26 4:41:33 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Cook Jennifer E. sold $13,156,008 worth of shares (148,589 units at $88.54) as part of a pre-agreed trading plan and exercised 148,589 shares at a strike of $24.96 (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    7/13/26 4:40:35 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Valantine Hannah was granted 3,990 shares, exercised 2,808 shares at a strike of $41.73 and sold $341,524 worth of shares (5,004 units at $68.25) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 9,259 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/24/26 6:06:22 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Leadership Updates

    Live Leadership Updates

    View All

    BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

    PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope

    7/23/24 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

    The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci

    5/2/24 7:00:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Pharma, Inc. Appoints Pioneering National Leader in Genomics and Workforce Diversity Hannah Valantine to its Board of Directors

    PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation

    10/25/21 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Financials

    Live finance-specific insights

    View All

    BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

    - Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a business of KKR, with an initial conversion price of approximately $138 per share (more than 100% premium to Company’s 30-day VWAP) - The financing significantly strengthens the Company’s balance sheet, enabling it to efficiently allocate capital across its highest return opportunities - The financing comes at a pivotal moment for the Company, as Attruby® continues to grow into a multi-billion-dollar blockbuster drug, and as BridgeBio prepares for three additional potential blockbuster U.S. product launches over the next 12 months across BBP-418 for LGMD2I/R9, encaleret for ADH1, and infigr

    7/1/26 7:30:00 AM ET
    $BBIO
    $KKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates

    $194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentumContinued broad uptake among all patient types and HCP segments with particularly strong and growing demand in treatment naïve patients; global launch gaining traction with recent Brazil approvalReal-world evidence reinforces the differentiation demonstrated in trial data. Analysis recently released on medRxiv.org shows Attruby reduces diuretic intensification by 43% compared to tafamidis; in addition, an independent real world evidence study presented at SCAI also revealed statistically s

    5/7/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET

    PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of t

    4/30/26 7:30:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    11/6/24 5:04:05 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    9/17/24 6:41:54 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BridgeBio Pharma Inc.

    SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)

    8/20/24 8:42:04 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care